Immunotherapies in the management of epidermal growth factor receptor mutated non-small cell lung cancer: a role will be found?

Ítems similars

• Cetuximab in advanced non-small cell lung cancer (NSCLC): the showdown?
  per: Sgambato, Assunta, et al.
  Publicat: (2014)
• Management of non-small cell lung cancer harboring epidermal growth factor receptor mutations in the era of first-line osimertinib
  per: Hakozaki, Taiki, et al.
  Publicat: (2019)
• Treating epidermal growth factor receptor-mutated non-small cell lung cancer—is dacomitinib the winner?
  per: Dempke, Wolfram C. M., et al.
  Publicat: (2017)
• Somatic mutations of the epidermal growth factor receptor and non‐small‐cell lung cancer
  per: Zhang, Xiaozhu, et al.
  Publicat: (2007)
• J-ALEX trial will crown alectinib as the standard choice for anaplastic lymphoma kinase positive untreated non-small cell lung cancer patients?
  per: Gridelli, Cesare, et al.
  Publicat: (2018)